Bill Lis joined Portola Pharmaceuticals in 2008, became chief operating officer in August 2009 and was named CEO in May 2010. A Philadelphia native, Lis previously worked at Scios, COR Therapeutics/Millennium Pharmaceuticals, Rhone-Poulenc Rorer and Ethicon Endo-Surgery. He is one of many former COR employees, including several key scientists, to join Portola. The company last month struck a potential $553 million deal with Biogen Idec around so-called Syk inhibitors that play key roles in autoimmune and inflammatory diseases.
No comments:
Post a Comment